Surface modification of electrodes by carbon nanotubes and gold and silver nanoparticles in monoaminoxidase biosensors for the determination of some antidepressants

Medyantseva, É. P.; Брусницын, Д. В.; Варламова, Р. М.; Максимов, А. А.; Коновалова, О. А.; Budnikov, H. C.

doi:10.1134/s1061934817040086

Cited by 16 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbon nanotubes are molecules that comprise a single sheet of carbon atoms rolled up into a cylindrical shape. CNTs possess chemical and structural properties that render them good drug carrier systems for drug delivery to the CNS [ 60 , 61 ]. CNTs show high biocompatibility and solubility which are determined by certain parameters that include size, physical properties and morphology of the modified molecules.…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

Nanotechnology has aided in the advancement of drug delivery for the treatment of several neurological disorders including depression. Depression is a relatively common mental disorder which is characterized by a severe imbalance of neurotransmitters. Several current therapeutic regimens against depression display drawbacks which include low bioavailability, delayed therapeutic outcome, undesirable side effects and drug toxicity due to high doses. The blood–brain barrier limits the entry of the drugs into the brain matrix, resulting in low bioavailability and tissue damage due to drug accumulation. Due to their size and physico-chemical properties, nanotechnological drug delivery systems present a promising strategy to enhance the delivery of nanomedicines into the brain matrix, thereby improving bioavailability and limiting toxicity. Furthermore, ligand-complexed nanocarriers can improve drug specificity and antidepressant efficacy and reduce drug toxicity. Biopolymers and nanocarriers can also be employed to enhance controlled drug release and reduce the hepatic first-pass effect, hence reducing the dosing frequency. This manuscript reviews recent advances in different biopolymers, such as polysaccharides and other nanocarriers, for targeted antidepressant drug delivery to the brain. It probes nano-based strategies that can be employed to enhance the therapeutic efficacy of antidepressants through the oral, intranasal, and parenteral routes of administration.

show abstract

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tianeptine: 2017 Case report of Tianeptine use purchased on the internet in the United States [ 481 ]; gold and silver nanoparticle electrodes combined with amperometric monoaminoxidase biosensors for the determination of tianeptine and other antidepressant drugs (moclobemide and amitriptyline) [ 482 ]; 2018 case reports of two known tianeptine fatalities in the United States [ 483 ]; characteristics of Tianeptine exposures reported to the National Poison Data System - United States, 2000–2017 [ 484 , 485 ]; New York State Poison Control Centers experience with calls related to tianeptine [ 486 ].…”

Section: Routine and Improved Analyses Of Abused Substancesmentioning

confidence: 99%

Interpol review of controlled substances 2016–2019

Jones

Comparin

2020

Forensic Science International: Synergy

View full text Add to dashboard Cite

show abstract

“…Enzymatic inhibition is considered as the key point in clinical applications and drug therapy. Indeed, several drugs such as neostigmine, donepezil, allopurinol, methimazole and moclobemide induce the inhibition of target enzymes involved in various diseases [ 42 , 43 , 44 ]. Accordingly, sensitive biosensors based on enzyme inhibition are highly required to monitor these drugs.…”

Section: Diagnosis Of Inhibition Typementioning

confidence: 99%

“…In the last decade, the Medyantseva group have developed different amperometric biosensors based on immobilized MAO to monitor different drugs used as antidepressants [ 43 , 80 , 81 , 82 , 83 , 84 , 85 , 86 ] and nitrofuran drugs [ 87 ] in pharmaceutical tablets and urine samples ( Table 3 ).…”

Section: Application Of Electrochemical Biosensors Based On Enzymementioning

confidence: 99%

“…Recently the Medyantseva group developed two different MAO biosensors modified with nanomaterials for monitoring moclobemide, tianeptine and amitriptyline antidepressants drugs in urine and in pharmaceutical tablets. In the first biosensor, they used screen-printed electrode modified with MWCNTs, gold and silver nanoparticles [ 43 ]. Using this biosensor, the antidepressants were determined in the concentration range of 5 × 10 −9 –10 −4 M with a detection limit of 8 × 10 −10 M. In the other biosensor, they modified screen-printed electrode with carbon nanotubes (CNTs) and AgNPs.…”

Section: Application Of Electrochemical Biosensors Based On Enzymementioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications

Harrad

Bourais

Mohammadi

et al. 2018

Sensors

108

View full text Add to dashboard Cite

A large number of enzyme inhibitors are used as drugs to treat several diseases such as gout, diabetes, AIDS, depression, Parkinson’s and Alzheimer’s diseases. Electrochemical biosensors based on enzyme inhibition are useful devices for an easy, fast and environment friendly monitoring of inhibitors like drugs. In the last decades, electrochemical biosensors have shown great potentials in the detection of different drugs like neostigmine, ketoconazole, donepezil, allopurinol and many others. They attracted increasing attention due to the advantage of being high sensitive and accurate analytical tools, able to reach low detection limits and the possibility to be performed on real samples. This review will spotlight the research conducted in the past 10 years (2007–2017) on inhibition based enzymatic electrochemical biosensors for the analysis of different drugs. New assays based on novel bio-devices will be debated. Moreover, the exploration of the recent graphical approach in diagnosis of reversible and irreversible inhibition mechanism will be discussed. The accurate and the fast diagnosis of inhibition type will help researchers in further drug design improvements and the identification of new molecules that will serve as new enzyme targets.

show abstract

Surface modification of electrodes by carbon nanotubes and gold and silver nanoparticles in monoaminoxidase biosensors for the determination of some antidepressants

Cited by 16 publications

References 25 publications

Advances in Nano-Enabled Platforms for the Treatment of Depression

Advances in Nano-Enabled Platforms for the Treatment of Depression

Interpol review of controlled substances 2016–2019

Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications

Contact Info

Product

Resources

About